Verastem’s Earnings Call Contradictions: Partnership Uncertainty, Fda Approval Shifts, and Financial Timeline Revisions

Date of Call: Aug 6, 2026

Financials Results

• Revenue: $25.1 million in net product revenue
• EPS: $0.31 per share diluted (non-GAAP adjusted net loss), compared to $0.62 per share diluted loss in the prior year quarter

Guidance:

• Expect LGSOC business to become self-sustaining by end of 2026, with CO-PACK revenues funding commercial ops and clinical trials.
• SG&A expenses expected to remain roughly same quarterly throughout 2026.
• Sufficient capital to fund operations into second half of 2027.
• Expect a meaningful data update on VS-7375 in October, including response rates across three lead tumor types.

Business Commentary:

Revenue Growth and Commercial Strategy:

• Verastem Oncology reported net product revenues of $25.1 million for Q2 2026, reflecting a rebound and growth in the commercial business.
• The growth was driven by changes in commercial strategy, increased physician confidence in initiating treatment, and an increase in patient refills.

Financial Strengthening and Strategic Flexibility:

• The company secured up to $75 million in funding through a non-dilutive royalty financing agreement and received a $15 million milestone payment from Secura Bio.
• These financial moves strengthen the balance sheet, provide strategic flexibility, and support ongoing commercial and development activities.

Pipeline Progress and Data Updates:

• Verastem Oncology advanced its pipeline with positive updates on the RAMP 205 pancreatic cancer data and progress on VS-7375, an oral KRAS G12D inhibitor.
• The company is focused on advancing treatment options for KRAS G12D-driven cancers with a combination that targets the biology of these cancers without unnecessary toxicities.

Operational Execution and Development Program:

• Operationally, Verastem completed target enrollment in key cancer cohorts for VS-7375 and received FDA Fast Track designation for non-small cell lung cancer.
• This demonstrates the company's ability to execute its development program efficiently, positioning it well for future clinical data updates and trials.

Sentiment Analysis:

Overall Tone: Positive

• Management described a 'strong second quarter with meaningful progress,' 'meaningful rebound with significant quarter-over-quarter growth,' and being 'encouraged that the changes we made are having an impact.' They also noted 'disciplined execution across the organization' and 'momentum continue in Q3.'

Q&A:

• Question from Eric Schmidt (Cantor Fitzgerald): Can you talk about partnership activity in the G12D space and any updates on potential collaborations?
  Response: Working on partnership details with Erasca; evaluating various options including PRMT5; have considerable inbound interest; the recent financing provides strategic flexibility.

• Question from Eric Schmidt (Cantor Fitzgerald): Is the current gross margin run rate reasonable going forward?
  Response: Yes, the current run rate is reasonable and indicative of future expectations, as cost of sales is mostly royalty-based with relatively high product margins.

• Question from Michelle (Guggenheim): Is a 30% overall response rate and six months durability still the right framing for accelerated approval across indications?
  Response: Yes, that is a very good guidepost, supported by recent approvals and the importance of both activity and tolerability.

• Question from Josh (RBC Capital Markets): How do you feel about the translatability of ORR data from the GenFleet China study to the U.S. population?
  Response: The drug is active; U.S. data from other products is the key benchmark; expect the October update to provide clarity.

• Question from Basil (Jefferies): What drove the strong CO-PACK revenue: new starts or improved duration of therapy?
  Response: A bit of both, with meaningful new prescribers and consistent new patient starts, plus refill consistency indicating patients are staying on therapy longer.

• Question from Graig Suvannavejh (Mizuho): Which segment (new starts, refills, line of therapy) is a bigger contributor to sales? How will you differentiate VS-7375 in the G12D landscape?
  Response: All three are critically important; need a combination. For differentiation: intend to show better efficacy and significantly better tolerability vs. pan-RAS inhibitors; believe best-in-class profile vs. other G12D inhibitors based on preclinical and emerging clinical data.

• Question from Andres Maldonado (H.C. Wainwright): How much prescribing is moving into first recurrence? How are dose interruptions managed? What justifies VS-7375 monotherapy in CRC without an EGFR inhibitor?
  Response: Very encouraged by movement up in line of therapy in both academic and community settings. Dose interruptions are part of the trial; focus is on managing them to limit time off therapy. For CRC, VS-7375 will be developed as a combination with an EGFR inhibitor.

• Question from Analyst (BTIG): Are you inclined to strike another partnership for PRMT5 or license your own inhibitor? What is the FDA bar for approval?
  Response: Exploring all options for PRMT5 partnerships or licensing. For accelerated approval, a rule of thumb is 30% ORR with at least six months durability, though the totality of data including tolerability is critical.

• Question from Matthew (Alliance Global Partners): How will doctors decide between RAS inhibitors and trials like yours, and how will you differentiate your trials?
  Response: Decision is based on efficacy and tolerability; KOLs would recommend a G12D-specific drug like theirs due to the favorable tolerability profile seen in their data.

Contradiction Point 1

Partner Interest and Deal Progression for VS-7375

It impacts expectations regarding partnership certainty and deal progression for a key asset, potentially affecting funding and development plans.

Eric Schmidt (Cantor Fitzgerald) - Eric Schmidt (Cantor Fitzgerald)

2026Q2: The partnership with Erasca is still in progress, with details... being worked through. - Dan Paterson(CEO)

Could you provide updates on partnership activity for VS-7375 in the G12D space and the status of the potential collaboration with Erasca? - Eric Schmidt (Cantor)

2026Q1: Interest exists, but decisions often depend on competitive dynamics. - Dan Paterson(CEO)

Contradiction Point 2

FDA Alignment on Accelerated Approval Thresholds

It involves differing specifications of FDA requirements, which are crucial for understanding the regulatory pathway and likelihood of approval.

Analyst (BTIG) - Analyst (BTIG)

2026Q2: The FDA does not set specific bars... but historical accelerated approvals are typically based on an ORR >20-30% with at least six months durability. - Dr. Michael Kauffman(Chief Medical Officer)

What approval criteria has the FDA set across the TARGET-D trials? - Jeet Mukherjee (BTIG)

2026Q1: No specific discussions on thresholds, but historical precedents suggest an ORR of 25-30% with at least 6 months durability of response is typically approvable... - Michael Kauffman(Development President)

Contradiction Point 3

LGSOC Franchise Financial Sustainability Timeline

It directly impacts expectations regarding the financial self-sufficiency of a core franchise, influencing views on the need for future fundraising.

Eric Schmidt (Cantor Fitzgerald) - Eric Schmidt (Cantor Fitzgerald)

2026Q2: The recent non-dilutive financing provides strategic flexibility, allowing the company to avoid rushing into an equity financing at the current stock price. - Dan Paterson(CEO)

What updates can you share on partnership activity for VS-7375 in the G12D space and the potential collaboration with Erasca? - Graig Suvannavejh (Mizuho)

20260305-2025 Q4: The company believes the LGSOC franchise will be self-sustaining by the second half of 2026, funded by CO-PACK revenues, and therefore does not require additional fundraising. - Daniel Paterson(CEO)

Contradiction Point 4

Development Strategy for VS-7375 in Colorectal Cancer (CRC)

It reflects a strategic shift in how the asset is positioned for development, which could affect trial design, regulatory pathway, and competitive positioning.

Andres Maldonado (H.C. Wainwright) - Andres Maldonado (H.C. Wainwright)

2026Q2: The company does not intend to develop VS-7375 as a single agent in CRC. It will be developed in combination with an EGFR inhibitor, as that is what is needed in that setting. - Dan Paterson(CEO)

What justifies continuing VS-7375 monotherapy without EGFR inhibitors in CRC, given recent data? - Michael Schmidt (Guggenheim Partners)

20260305-2025 Q4: The primary regulatory goal is to move the drug into later lines (2L/3L) through accelerated pathways, then into frontline studies. While initial combinations (like with cetuximab) are being evaluated... - Michael Glen Kauffman(CMO)

Contradiction Point 5

Launch Performance and Patient Retention

It involves differing statements on early launch metrics, which are important for assessing product acceptance and commercial viability.

What insights does Basil (Jefferies) have on the earnings report? - Basil (Jefferies)

2026Q2: The growth was driven by... encouraging refill consistency, indicating patients are staying on therapy longer. - Dan Lyons(CCO)

What was the primary driver of the CO-PACK sales uptick in Q2: new patient starts or improved duration of therapy? - Xun Lee (H.C. Wainwright)

2025Q3: It is too early to comment definitively on retention or dropout rates. Patients starting at first recurrence may experience prolonged benefit, but more data is needed. - Daniel Paterson(CEO) and Matthew Ros(COO)